Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vi-polysaccharide vaccine responses in adults with specific antibody deficiency
ACTRN12621001059853Phase 4Completed
- Sponsor
- Melbourne Health
- Start
- Jan 2022
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of salmonella typhi capsular polysaccharide vaccine in selective antibody deficiency (SAD) and common variable immunodeficiency (CVID), sponsored by Melbourne Health. Primary endpoints: Humoral response in SAD and Cellular response in SAD. Started Jan 2022; status: completed.
02
Drugs
salmonella typhi capsular polysaccharide vaccine
03
Conditions
selective antibody deficiency (SAD)common variable immunodeficiency (CVID)
Beyond the preview
Go deeper on ACTRN12621001059853.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12621001059853.